Onkologie. 2012;35(1-2):24-6. Epub 2012 Jan 23.
Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Grenader T.
LINK
Source
Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
talgrenader65@hotmail.com
Abstract
BACKGROUND:
The aim of this retrospective study was to assess the efficacy and safety of the relatively old lowcost CMFVP regimen (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) as compared to newer and more costly chemotherapeutic agents.
PATIENTS AND METHODS:
An analysis of the medical records of female patients with metastatic breast cancers treated with a CMFVP combination at the Shaare Zedek Medical Center (SZMC) was performed. 32 patients with measurable metastatic disease were included in the analysis. The median age was 59.9 years (range 36-102 years). 20 of the patients had previously been treated with both anthracyclines and taxanes.
RESULTS:
Therapy was generally well tolerated and toxicity manageable. Median time to disease progression was 20.97 weeks (range 2-103 weeks). 6 patients (19%) demonstrated a partial response, and 7 patients (22%) had stable disease lasting 3 or more months for an overall clinical benefit of 41%. 4 of the 20 patients previously treated with both anthracyclines and taxanes had a partial response, and 4 patients had stable disease lasting 3 or more months for a clinical benefit of 40%.
CONCLUSION:
On the basis of this small retrospective survey, we conclude that CMFVP combination chemotherapy is both effective and safe in patients with metastatic breast cancer previously treated with both taxanes and anthracyclines.
Copyright © 2012 S. Karger AG, Basel.
- PMID:
- 22310341
- [PubMed - in process]